Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BillionToOneBLLN -0.25%15 Earnings Yield (Joel Greenblatt) % is 0.73% as of Jun. 2026, which is 83% above its 10-year median of 0.40. GuruFocus rates BLLN with a GF Score™ of 15/100. The stock has 4 warning signs investors should review. Among 212 Medical Diagnostics & Research companies, BillionToOne ranks better than 55.66% on this metric.
BillionToOne's Enterprise Value for the quarter that ended in Jun. 2026 was $5,213.6 Mil.
BillionToOne's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $37.9 Mil. BillionToOne's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was 0.73%.
The historical rank and industry rank for BillionToOne's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
BLLN'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -0.25 Med: 0.4 Max: 0.93
Current: 0.93
During the past 3 years, the highest Earnings Yield (Joel Greenblatt) of BillionToOne was 0.93%. The lowest was -0.25%. And the median was 0.40%.
BLLN's Earnings Yield (Joel Greenblatt) % is ranked better than 55.66% of 212
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.175
vs BLLN: 0.93
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. BillionToOne's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
BillionToOne Earnings Yield (Joel Greenblatt) % Related Terms
BillionToOne Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for BillionToOne's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, BillionToOne's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BillionToOne Earnings Yield (Joel Greenblatt) % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BillionToOne's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where BillionToOne's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
BillionToOnes Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
BillionToOne's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $37.9 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 0.73% mean?
BillionToOne (BLLN) has a Earnings Yield (Joel Greenblatt) % of 0.73% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on BillionToOne and its competitors. This is 83% above median its historical median of 0.40. According to the industry distribution chart, BillionToOne ranks #94 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 44.3%.
Is BillionToOne's Earnings Yield (Joel Greenblatt) % too high?
BillionToOne's current Earnings Yield (Joel Greenblatt) % of 0.73% is 83% above median its 10-year median of 0.40. Based on the distribution chart, BillionToOne ranks #94 out of 212 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, BillionToOne has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does BillionToOne's Earnings Yield (Joel Greenblatt) % compare to TWST and SHC?
According to the Medical Diagnostics & Research industry distribution chart, BillionToOne ranks #94 out of 212 companies for Earnings Yield (Joel Greenblatt) %. This puts BillionToOne in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Diagnostics & Research company?
A good Earnings Yield (Joel Greenblatt) % depends on the Medical Diagnostics & Research industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on BillionToOne and its competitors. BillionToOne's current Earnings Yield (Joel Greenblatt) % is 0.73%, which is 83% above median its own 10-year median of 0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BillionToOne stock overvalued right now?
BillionToOne (BLLN) has a current Earnings Yield (Joel Greenblatt) % of 0.73%. The current Earnings Yield (Joel Greenblatt) % is 0.73%, which is 83% above median its 10-year median of 0.40. BillionToOne's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For BillionToOne (BLLN), the current Earnings Yield (Joel Greenblatt) % is 0.73% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
15GF Score
Get the complete analysis for BLLN
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLLN has been successfully added to your 
